|[January 24, 2014]
Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit on Behalf of Investors of Aegerion Pharmaceuticals, Inc.
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP announces that a class action lawsuit has
been filed in the United States District Court for the District of
Massachusetts on behalf of a class (the "Class") comprising all
purchasers of the securities of Aegerion
Pharmaceuticals, Inc. ("Aegerion" or the "Company") (NASDAQ:AEGR)
between March 15, 2012 and January 9, 2014, inclusive (the "Class
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY
BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, OR
AT (212) 682-5340, OR BY EMAIL TO SHAREHOLDERS@GLANCYLAW.COM
TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR
MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Aegerion markets its cholesterol drug Juxtapid in the United States.
Juxtapid is the sole FDA-approved Aegerion product. Juxtapid was
approved by U.S. health regulators in December 2012 o treat patients
with homozygous familial hypercholesterolemia (HoFH), a rare genetic
disease that impairs the function of the receptor responsible for
removing LDL-C or "bad" cholesterol from the blood.
The Complaint alleges that Aegerion's marketing practices during the
Class Period were in violation of the Food, Drug, and Cosmetic Act
(FDCA), and that defendants made false and misleading statements or
failed to disclose to Aegerion investors that:
the Company marketed its drugs in violation of the FDCA; and
as a result, the Company faced heightened regulatory scrutiny by the
FDA and other governmental bodies.
On January 10, 2014, the Company received a subpoena from the U.S.
Department of Justice requesting documents regarding its marketing and
sale of Juxtapid. As a result of this news, Aegerion shares declined $
7.98 per share, or nearly 11%, to close at $65.77 per share on January
If you are a member of the Class described above, you may move the Court
no later than March 17, 2014, to serve as lead plaintiff; however, you
must meet certain legal requirements. To be a member of the Class,you
need not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the Class. If
you wish to learn more about this action or if you are a long-term
shareholder of Aegerion and have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to firstname.lastname@example.org,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To TMCnet.com's Homepage ]